Abstract: The application relates to a method for diagnosis of a chronic fatigue disease, e.g. CFS or CRF, comprising the step of determining the presence or absence of antibodies directed against ?-adrenergic receptor in a sample of the subject to be diagnosed, wherein the presence of antibodies directed against ?-adrenergic receptor is indicative of the chronic fatigue disease in said subject. Furthermore, the application relates to kits comprising ?-adrenergic receptor or an antigenic peptide thereof and the use of ?-adrenergic receptor or an antigenic peptide thereof for the diagnosis of a chronic fatigue disease.

Abstract: The application relates to a method for diagnosis of a chronic fatigue disease, e.g. CFS or CRF, comprising the step of determining the presence or absence of antibodies directed against ?-adrenergic receptor in a sample of the subject to be diagnosed, wherein the presence of antibodies directed against ?-adrenergic receptor is indicative of the chronic fatigue disease in said subject. Furthermore, the application relates to kits comprising ?-adrenergic receptor or an antigenic peptide thereof and the use of ?-adrenergic receptor or an antigenic peptide thereof for the diagnosis of a chronic fatigue disease.

Abstract: The present invention relates to an in vitro method for diagnosing Chronic Fatigue Syndrome by determining the presence, absence or the amount of at least one marker characteristic of an Epstein-Barr virus (EBV) infection in a sample obtained from the body of an individual. Specifically, the marker characteristic of EBV infection is selected from the group consisting of EBNA1, EBNA3, EBNA4, EBNA6, BZLF1, LMP1 and VP26. Furthermore, the invention relates to a device for the diagnosis of Chronic Fatigue Syndrome, wherein the device comprises a solid phase having immobilized thereon at least one marker or protein fragment thereof, wherein the marker is selected from the group consisting of EBNA1, EBNA3, EBNA4, EBNA6, BZLF1, LMP1 and VP26. In addition, the invention relates to the use of at least one marker or a protein fragment thereof for diagnosis of Chronic Fatigue, wherein the marker is selected from the group consisting of EBNA1 EBNA3, EBNA4, EBNA6, BZLF1, LMP1 and VP26.

Abstract: A method for the generation of antigen-specific T-cell preparations for adoptive therapy is provided, comprising the steps of obtaining lymphoid cells from the bone marrow of a patient in a first step, expanding the lymphoid cells in cell culture medium ex-vivo in the presence of at least one of IL2 and IL7 and or more antigens, yielding a T-cell preparation, and isolating the T-cell preparation from the culture medium in an isolation step. T-cell preparations provided according to the inventive method, and the use of such T-cell preparations for the treatment of infectious disease and cancer is also provided.